Company profile
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Privately held: no public share price · China
Assets
(4 total)
4Total Assets
0Approved
4Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | PD-1Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 3 | TubulinSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 3 | mTOR (mechanistic target of rapamycin complex 1), via FKBP-12Small molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 3 | IL-4R-alphaMonoclonal antibody | Atopic Dermatitis |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.